Pure Financial Advisors LLC Has $811,000 Stake in Stryker Corporation (NYSE:SYK)

Pure Financial Advisors LLC increased its stake in Stryker Corporation (NYSE:SYK - Free Report) by 106.4% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,178 shares of the medical technology company's stock after acquiring an additional 1,123 shares during the period. Pure Financial Advisors LLC's holdings in Stryker were worth $811,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Stryker in the 4th quarter worth $25,000. Capital A Wealth Management LLC purchased a new stake in Stryker during the fourth quarter valued at about $26,000. Rakuten Securities Inc. increased its stake in Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after acquiring an additional 68 shares during the last quarter. City Holding Co. raised its holdings in shares of Stryker by 528.6% in the 1st quarter. City Holding Co. now owns 88 shares of the medical technology company's stock worth $33,000 after purchasing an additional 74 shares during the period. Finally, VSM Wealth Advisory LLC acquired a new position in shares of Stryker in the 4th quarter valued at about $36,000. Institutional investors and hedge funds own 77.09% of the company's stock.

Stryker Stock Performance

Shares of SYK stock traded up $2.16 during trading on Monday, reaching $395.71. 1,151,593 shares of the company's stock were exchanged, compared to its average volume of 1,343,973. Stryker Corporation has a twelve month low of $314.93 and a twelve month high of $406.19. The stock has a market capitalization of $151.04 billion, a PE ratio of 53.47, a PEG ratio of 2.97 and a beta of 0.91. The firm's fifty day moving average price is $380.12 and its 200-day moving average price is $375.60. The company has a quick ratio of 1.00, a current ratio of 1.64 and a debt-to-equity ratio of 0.69.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. Stryker had a net margin of 12.31% and a return on equity of 23.74%. The company had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the prior year, the firm posted $2.50 EPS. The firm's quarterly revenue was up 11.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.85%. The ex-dividend date of this dividend is Monday, June 30th. Stryker's dividend payout ratio is currently 45.41%.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the transaction, the director directly owned 3,417,326 shares in the company, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 5.20% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. The Goldman Sachs Group set a $422.00 price target on shares of Stryker in a report on Tuesday, March 4th. Wall Street Zen lowered shares of Stryker from a "buy" rating to a "hold" rating in a report on Friday. Truist Financial increased their price target on Stryker from $390.00 to $400.00 and gave the company a "hold" rating in a report on Monday, May 5th. BTIG Research set a $403.00 price objective on Stryker and gave the stock a "buy" rating in a research note on Monday, April 14th. Finally, Roth Mkm increased their target price on Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $427.30.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.